Panel Discussion: The Role of AI in the Future of Companion Diagnostics

• Companion diagnostics have traditionally relied on single-gene or single-analyte biomarkers to identify the right patients for a therapy. The field is now evolving toward RNA expression, complex signatures, digital pathology, multi-omic data, and AI-enabled approaches to patient selection
• This panel will explore the future of companion diagnostics as biomarkers become increasingly complex, multimodal, and AI-derived. Importantly, how AI-enabled CDx can be developed, validated, and regulated without compromising the rigor required for treatment decisions

Speakers:

Carla Kantara

Vice President & Head, Enterprise Partnering, Global Biopharma Business Development

Caris Life Sciences

Travis Wager

Co-Founder, President & Chief Scientific Officer

Rgenta Therapeutics

Milan Radovich

Chief Scientific Officer & Head, Business Development

Caris Life Sciences

Julie Ramage

Principal

Harbor Precision Genomics Consulting